Skip to main content
Premium Trial:

Request an Annual Quote

BAG Diagnostics Gets CE Mark for Coronavirus MDx Test

NEW YORK – Germany's BAG Diagnostics said on Thursday that its ViroQ SARS-CoV-2 rapid PCR test has received CE IVD marking.

BAG Diagnostics' test is designed to detect SARS-CoV-2 genes E and RdRP in respiratory samples, according to the company's website. The company said that the assay's ability to detect a housekeeping gene that occurs in all cells can determine whether sufficient cell material is available for valid results, helping to eliminate false negatives.

Each kit is designed to perform 100 tests, and the kits can be shipped at ambient temperature but necessitate storage at -20° C. BAG Diagnostics said the test should be able to be performed with all RNA isolation kits and has been tested with kits from Qiagen and Sigma-Aldrich.

In addition, the three fluorescent dyes used in the assay are compatible with common real-time PCR cyclers and have been tested on Thermo Fisher Scientific's QuantStudio 6, Bio-Rad's CFX 96TM, and Roche's Lightcycler 480.

The company said that the test will be made available in all territories recognizing CE marking.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.